Home » Stocks » CURR

CURE Pharmaceutical Holding Corp. (CURR)

Stock Price: $1.30 USD -0.04 (-2.99%)
Updated Jan 15, 2021 3:52 PM EST - Market closed
Market Cap 69.20M
Revenue (ttm) 1.08M
Net Income (ttm) -15.04M
Shares Out 41.34M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.30
Previous Close $1.34
Change ($) -0.04
Change (%) -2.99%
Day's Open 1.34
Day's Range 1.26 - 1.43
Day's Volume 56,857
52-Week Range 0.96 - 2.85

News

Hide News
  • All
  • Videos
  • Press Releases
Business Wire - 1 week ago

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development compa...

Business Wire - 1 month ago

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTCQB: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness produc...

Business Wire - 1 month ago

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products...

Business Wire - 2 months ago

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Closes $10 Million Financing

Business Wire - 2 months ago

LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding (OTCQB: CURR) wholly owned subsidiary Sera Labs is challenging the status quo of the health and wellness sector by br...

Business Wire - 3 months ago

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October.

GlobeNewsWire - 4 months ago

- CURE will present at the LD 500 Virtual Conference, September 4 at 8:20 am PDT - 

Business Wire - 5 months ago

SHERMAN OAKS, Calif.--(BUSINESS WIRE)-- #Beauty--Sera Labs, a Leader in the CBD Industry to be acquired by CURE Pharmaceutical in a $20 Million Transaction

GlobeNewsWire - 6 months ago

Significantly higher serum concentration and absorption Showcases CUREform™ encapsulation and oral thin film technology Significantly higher serum concentration and absorption Showcases CUREfo...

GlobeNewsWire - 6 months ago

OXNARD, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today announced that its 25,000 square foot manufactu...

GlobeNewsWire - 7 months ago

- Jonathan Berlent Appointed to Newly Created Role - - Jonathan Berlent Appointed to Newly Created Role -

GlobeNewsWire - 7 months ago

OXNARD, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR), an innovative drug delivery company that is developing novel ways to deliver active ingredien...

About CURR

CURE Pharmaceutical Holding, an integrated drug delivery and development company, focuses on improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. The company is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. It offers CURE 3068 (CUREfilm Sleep), a melatonin-containing sleep aid CUREfilm oral dissolving film (ODF) that is used as a dietary supplement under the brand name ID Life Sleep Strips; and CURE... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2011
CEO
Robert Davidson
Employees
18
Stock Exchange
OTCMKTS
Ticker Symbol
CURR
Full Company Profile

Financial Performance

In 2019, CURR's revenue was $623,000, an increase of 6.68% compared to the previous year's $584,000. Losses were -$21.36 million, 105.4% more than in 2018.

Financial Statements